<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="54273" name="tafamidis"><HDS>Launched</HDS><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><RegulatoryDesignation id="14">Sakigake</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="621" type="primary">Amyloid protein deposition inhibitor</Action><Action id="11256" type="primary">Transthyretin modulator</Action></Actions><Indications><Indication id="3392" type="primary">Lipotoxic cardiomyopathy</Indication><Indication id="3399" type="primary">Familial amyloid neuropathy</Indication><Indication id="1143" type="secondary">Amyloidosis</Indication></Indications><Entities><Entity>Chemical</Entity></Entities><OriginatorCompany id="21102">Scripps Research Institute</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>